Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | DPP4 | P27487 | 6/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.38 |
| ▸ | VHL | P40337 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13237028 | 1.00 | ATM (0.69) | ATMMMP2ANPEPPIK3CDDPP4 | |
| SCHEMBL23897306 | 0.85 | ATM (0.65) | ATMMMP2ANPEPPIK3CDDPP4 | |
| SCHEMBL8203665 | 0.84 | ATM (0.48) | ATMMMP2ANPEPALDH1A1PIN1 | |
| SCHEMBL3058678 | 0.84 | ANPEP (0.66) | ATMMMP2ANPEPPIN1 | |
| SCHEMBL21105707 | 0.83 | ATM (0.47) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL12562519 | 0.83 | ATM (0.74) | ATMMMP2ANPEPPIK3CDDPP4 | |
| SCHEMBL29489487 | 0.83 | ATM (0.47) | ATMPIK3CDDPP4DPP8DPP9 | |
| Oxaceprol SCHEMBL25978 | 0.82 | ATM (1.00) | ATMMMP2ANPEPPIK3CDDPP4 | |
| Oxaceprol SCHEMBL3780150 | 0.82 | ATM (1.00) | ATMMMP2ANPEPPIK3CDDPP4 | |
| Oxaceprol SCHEMBL25977 | 0.82 | ATM (1.00) | ATMMMP2ANPEPPIK3CDDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101990-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD134+ CELLS | Magenta Therapeutics, Inc. (US) | 2021-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101990-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD134+ CELLS | CD2, CD47, CD22 | ATM 4473/4885MMP2 4595/4885ANPEP 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.